Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 2
1995 12
1996 37
1997 60
1998 84
1999 94
2000 103
2001 118
2002 146
2003 132
2004 162
2005 176
2006 212
2007 206
2008 211
2009 235
2010 261
2011 260
2012 222
2013 245
2014 245
2015 279
2016 294
2017 271
2018 286
2019 311
2020 309
2021 307
2022 276
2023 278
2024 260
2025 290
2026 155

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,799 results

Results by year

Filters applied: . Clear all
Page 1
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.
Phillips KA, Kotsopoulos J, Domchek SM, Terry MB, Chamberlain JA, Bassett JK, Aeilts AM, Andrulis IL, Buys SS, Cui W, Daly MB, Eisen AF, Foulkes WD, Friedlander ML, Gronwald J, Hopper JL, John EM, Karlan BY, Kim RH, Kurian AW, Lubinski J, Metcalfe K, Nathanson KL, Singer CF, Southey MC, Symecko H, Tung N, Narod SA, Milne RL; Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the Basser Center University of Pennsylvania Registry, and the Breast Cancer Family Registry; Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the Basser Center University of Pennsylvania Registry and the Breast Cancer Family Registry. Phillips KA, et al. J Clin Oncol. 2025 Feb;43(4):422-431. doi: 10.1200/JCO.24.00176. Epub 2024 Oct 2. J Clin Oncol. 2025. PMID: 39356978 Free PMC article.
PURPOSE: It is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germline BRCA1 or BRCA2 mutation carriers. METHODS: Using pooled observational data from four prospective cohort studies, associat …
PURPOSE: It is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germ …
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).
Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP, Caron O, Stoppa-Lyonnet D, Berthet P, Faivre L, Bonadona V, Buecher B, Coupier I, Gladieff L, Gesta P, Eisinger F, Frénay M, Luporsi E, Lortholary A, Colas C, Dugast C, Longy M, Pujol P, Tinat J; GENEPSO; Lidereau R, Andrieu N. Lecarpentier J, et al. Breast Cancer Res. 2012 Jul 3;14(4):R99. doi: 10.1186/bcr3218. Breast Cancer Res. 2012. PMID: 22762150 Free PMC article.
INTRODUCTION: Mutations in BRCA1 and BRCA2 confer a high risk of breast cancer (BC), but the magnitude of this risk seems to vary according to the study and various factors. ...CONCLUSIONS: Our findings show that, taking into account envi …
INTRODUCTION: Mutations in BRCA1 and BRCA2 confer a high risk of breast cancer (BC), but the magnitude of …
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. King MC, et al. Science. 2003 Oct 24;302(5645):643-6. doi: 10.1126/science.1088759. Science. 2003. PMID: 14576434
Risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2. ...Lifetime risks of ovarian cancer were 54% for BRCA1 and 23% for BRCA2 m …
Risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor …
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.
Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, Karlan BY, Aeilts A, Eng C, Bordeleau L, Foulkes WD, Tung N, Couch FJ, Fruscio R, Ramon Y Cajal T, Singer CF, Neuhausen SL, Zakalik D, Cybulski C, Gronwald J, Huzarski T, Stempa K, Dungan J, Cullinane C, Olopade OI, Metcalfe K, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Lubinski J, et al. JAMA Oncol. 2024 Apr 1;10(4):493-499. doi: 10.1001/jamaoncol.2023.6944. JAMA Oncol. 2024. PMID: 38421676 Free PMC article.
IMPORTANCE: Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast ca …
IMPORTANCE: Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 …
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.
Kotsopoulos J, Seca M, Gronwald J, Huzarski T, Møller P, Kim RH, Singer CF, Karlan B, Aeilts A, Ramón Y Cajal T, Pal T, Eisen A, Bordeleau L, Foulkes WD, Tung N, Couch F, Neuhausen SL, Zakalik D, Cybulski C, Olopade O, Metcalfe K, Fruscio R, Sun P, Lubinski J, Narod SA. Kotsopoulos J, et al. J Natl Cancer Inst. 2026 May 1;118(5):856-864. doi: 10.1093/jnci/djaf363. J Natl Cancer Inst. 2026. PMID: 41403285
Menopausal hormone replacement therapy (HRT) is an effective way to mitigate the adverse outcomes of early menopause; however, the safety of menopausal HRT on breast cancer risk in this population has not been established. METHODS: We conducted a prospective …
Menopausal hormone replacement therapy (HRT) is an effective way to mitigate the adverse outcomes of early menopause; however, the safety of …
Risk-Reducing Bilateral Mastectomy and Mortality in Carriers of BRCA1 and BRCA2 Variants: A Systematic Review and Meta-Analysis.
O'Reilly C, McGarry JL, Zaborowski AM, Davey MG, Evoy D, Rothwell J, McCartan D, Rutherford CL, Boland MR, Prichard RS. O'Reilly C, et al. JAMA Surg. 2026 Mar 1;161(3):260-267. doi: 10.1001/jamasurg.2025.5929. JAMA Surg. 2026. PMID: 41499127
STUDY SELECTION: Eligible studies compared female carriers of BRCA1 and BRCA2 pathogenic variants who underwent risk-reducing bilateral mastectomy with those who did not and reported overall mortality or breast cancer-specific mortality. ...MAIN …
STUDY SELECTION: Eligible studies compared female carriers of BRCA1 and BRCA2 pathogenic variants who underwent risk-re …
Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies.
Pan H, He Z, Ling L, Ding Q, Chen L, Zha X, Zhou W, Liu X, Wang S. Pan H, et al. Cancer Epidemiol. 2014 Feb;38(1):1-8. doi: 10.1016/j.canep.2013.11.004. Epub 2013 Dec 12. Cancer Epidemiol. 2014. PMID: 24332935 Review.
Although reproductive factors are among the most well-established risk factors for breast cancer in the general population, it is still a matter for debate whether these factors act as risk modifiers among BRCA1 or BRCA2 mutation carriers …
Although reproductive factors are among the most well-established risk factors for breast cancer in the general populat …
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
Stjepanovic N, Lubinski J, Moller P, Randall Armel S, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J, Sun P, Sun S, Eisen A, Narod SA; Hereditary Breast Cancer Clinical Study Group. Stjepanovic N, et al. Breast Cancer Res Treat. 2021 Jun;187(2):515-523. doi: 10.1007/s10549-020-06072-9. Epub 2021 Jan 10. Breast Cancer Res Treat. 2021. PMID: 33423179
PURPOSE: It is not known whether the risk of breast cancer among BRCA1 and BRCA2 mutation carriers after age 60 is high enough to justify intensive screening or prophylactic surgery. ...The cumulative risk of invasive breast can …
PURPOSE: It is not known whether the risk of breast cancer among BRCA1 and BRCA2 mutation carriers after …
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.
Apostol AI, Kotsopoulos J, Gronwald J, Kim RH, Karlan BY, Aeilts A, Cajal TRY, Pal T, Eisen A, Bordeleau L, Foulkes WD, Couch F, Zakalik D, Fruscio R, Sun P, Lubinski J, Tung N, Singer CF, Moller P, Dominguez-Valentin M, Narod SA, Metcalfe K; Hereditary Breast Cancer Clinical Study Group. Apostol AI, et al. Gynecol Oncol. 2025 Oct;201:44-52. doi: 10.1016/j.ygyno.2025.07.030. Epub 2025 Aug 9. Gynecol Oncol. 2025. PMID: 40784323
Among BRCA2 carriers, the 15-year ovarian cancer risk was 2.0 % in both groups. CONCLUSIONS: Ovarian cancer risk remains high in BRCA1/2 carriers following breast cancer diagnosis. For BRCA1 mutation carriers, the …
Among BRCA2 carriers, the 15-year ovarian cancer risk was 2.0 % in both groups. CONCLUSIONS: Ovarian cancer r …
Breast cancer risk-assessment models.
Evans DG, Howell A. Evans DG, et al. Breast Cancer Res. 2007;9(5):213. doi: 10.1186/bcr1750. Breast Cancer Res. 2007. PMID: 17888188 Free PMC article. Review.
There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRC …
There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cance …
5,799 results